Abstract #0267
Whole-gland MRI-guided transurethral ultrasound ablation of low-risk prostate cancer: preliminary results from a multi-center phase I clinical trial
Matthias C. Roethke 1 , Mathieu Burtnyk 2 , Timur H. Kuru 3 , Maya Wolf 1 , Gencay Hatiboglu 3 , Michele Billia 4 , Cesare Romagnoli 5 , Sascha Pahernik 3 , Joseph Chin 4 , and Heinz-Peter Schlemmer 1
1
Radiology, German Cancer Research Center
(DKFZ), Heidelberg, Germany,
2
Profound
Medical Inc., Toronto, Ontario, Canada,
3
Urology,
University Hospital Heidelberg, Germany,
4
Urology,
Western University UWO, London Health Sciences Center,
London Victoria Hospital, Ontario, Canada,
5
Radiology,
Western University UWO, London Health Sciences Center,
London Victoria Hospital, Ontario, Canada
MRI-guided transurethral ultrasound ablation is a novel
minimally-invasive treatment for localised prostate
cancer, where a volume of thermal ablation is generated
and shaped precisely to the prostate using MR-thermometry
feedback control. A phase I safety and feasibility
clinical trial was initiated, with 16 patients treated
to-date and no cases of urinary incontinence or rectal
injury. Median treatment time and prostate volume were
29min and 45ml. Spatial control of the ablation volume
was -0.11.4mm (+0.5/-1.2ml), with good correlation to
the non-perfused volume on post-treatment CE-MRI. At
1-month, median PSA reduced by 87% to 0.7ng/ml, with the
nadir expected by 6 months.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
